Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
The purpose of this study is to assess and compare the safety of continuous and daily
 subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned
 vascular interventional procedures; and to determine the effect of Remodulin on wound healing
 and treadmill walk distance.
Patients with Stage III or IV critical limb ischemia due to documented peripheral arterial
 disease with no planned interventional vascular procedures